GSK, endometrial cancer and european commission
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line treatment for locally advanced and metastatic NSCLC with exon 19 deletions or exon 21 L858R substitutions.
Flow Space on MSN9h
Is Bleeding After Menopause Always Cancer? Here's What You Should KnowIf somebody has gone through menopause and then bleeding reappears, it’s really important that the patient does not make ...
The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...
Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...
Getty Deaths from uterine cancer are also on the rise, as the study says it’s “one of the few cancers with increasing mortality; from 2013 to 2022 the death rate rose by 1.5% per year.” ...
Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback